Improved Outcomes Among Newly Diagnosed Patients with FLT3-ITD Mutated AML Treated with Contemporary Therapy: Revisiting the ELN Adverse Risk Classification.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of hematology"
DOI: 10.1002/ajh.26451
Abstract: Mutations in in fms-like tyrosine kinase 3 (FLT3) gene are common genomic alterations in acute myeloid leukemia (AML). FLT3 internal tandem duplication mutations (FLT3-ITD) have consistently been shown to be adversely prognostic, particularly those with… read more here.
Keywords: eln adverse; patients flt3; adverse risk; flt3 mutations ... See more keywords